Scarica l'app Stockscreener
11.88
0.42%
-0.05
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
AMRX Should I Buy - Intellectia AI
3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX) - Yahoo Finance
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock? - Yahoo Finance
Here's why Amneal Pharmaceuticals (AMRX) is a strong growth stock - MSN
Amneal Pharmaceuticals' (NASDAQ:AMRX) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance
AMRX growth drivers: Generics, biosimilars, and Crexont - MSN
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness - Sahm
Amneal (AMRX) director Deborah Autor sells 34,819 shares at $12.94 avg - Stock Titan
[144] Amneal Pharmaceuticals, Inc. SEC Filing - Stock Titan
Do options traders know something about Amneal stock we don't? - MSN
Amneal (AMRX) Q3 2025 Earnings Call Transcript - AOL.com
AMRX SEC FilingsAmneal Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook - MSN
Amneal Pharmaceuticals (AMRX) Profit Rebound Challenges Concerns Over Earnings Quality - Sahm
[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Amneal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director BUCHI J KEVIN - Moomoo
Amneal (NYSE: AMRX) director exercises 34,819 RSUs and receives new grant - Stock Titan
Amneal (NYSE: AMRX) director settles RSUs, now holds 128,479 shares - Stock Titan
Amneal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director George Jeffrey P. - Moomoo
Amneal (AMRX) director Jeffrey George exercises 34,819 RSUs, receives 19,824 new units - Stock Titan
Amneal (AMRX) director exercises RSUs, now holds 260,252 shares - Stock Titan
Director boosts stake with 34,819 shares in Amneal (NYSE: AMRX) - Stock Titan
Amneal (NYSE: AMRX) director exercises 48,747 RSUs and receives 30,837-unit grant - Stock Titan
Amneal (NYSE: AMRX) director converts RSUs to shares and gets new grant - Stock Titan
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised) - Yahoo Finance
Amneal Shareholders Back Board, Pay and Auditor at Meeting - TipRanks
Amneal Pharmaceuticals Q1 2026 & M&A announcement Earnings Call Transcript - MarketBeat
Amneal Pharmaceuticals (NASDAQ: AMRX) posts Q1 profit surge and inks $375M Kashiv acquisition - Stock Titan
Drugmaker Amneal posts $62M profit as specialty-drug sales rise 23% - Stock Titan
Amneal (NASDAQ: AMRX) investors back directors, say-on-pay and EY as auditor - Stock Titan
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, vs. FactSet Est of $0.17 - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q1 Revenue $722.5M, vs. FactSet Est of $719.7M - marketscreener.com
Amneal (NASDAQ: AMRX) Q1 2026 profit soars as margins rise and guidance held - Stock Titan
Amneal Reports First Quarter 2026 Financial Results - The Manila Times
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q1 Revenue $722.5M, Vs. FactSet Est of $719.7M - Moomoo
Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.27 per Share, Vs. FactSet Est of $0.22 - Moomoo
Number of shareholders of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vishrut Awasthi Joins Amneal Pharmaceuticals to Lead India Strategy and Business Development - hrtoday.in
Amneal Pharmaceuticals Kashiv Deal Puts Biosimilar Growth And Valuation In Focus - Yahoo Finance
Do Options Traders Know Something About Amneal Stock We Don't? - Yahoo Finance
How The Amneal Pharmaceuticals (AMRX) Story Is Shifting Around The New US$17 Price Target - Yahoo Finance
Earnings call transcript: Amneal Pharma Q1 2026 Surpasses EPS Forecast By Investing.com - Investing.com Nigeria
Earnings call transcript: Amneal Pharma Q1 2026 Surpasses EPS Forecast - Investing.com
Amneal Pharmaceuticals Q1 2026 earnings preview - MSN
How CREXONT’s Positive Phase 4 Data and Reaffirmed Outlook Could Shape Amneal Pharmaceuticals (AMRX) Investors - Sahm
0.28%
0.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):